Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
(Stocks hitting 52-week highs on April 26)
- Genprex Inc (NASDAQ:GNPX)
- Integra Lifesciences Holdings Corp (NASDAQ:IART)
- Novocure Ltd (NASDAQ:NVCR) (following the release of its FQ1 results
Down In The Dumps
(Stocks hitting 52-week lows on April 26)
- Aileron Therapeutics Inc (NASDAQ:ALRN)
- Citius Pharmaceuticals Inc (NASDAQ:CTXR)
- Cocrystal Pharma Inc (NASDAQ:COCP)
- Invivo Therapeutics Holdings Corp (NASDAQ:NVIV)
- Onconova Therapeutics Inc (NASDAQ:ONTX)
- PAVmed Inc (NASDAQ:PAVM)
Stocks In Focus
Intra-Cellular Rises on AAN Poster Presentation
Intra-Cellular Therapies Inc (NASDAQ:ITCI) made a poster presentation on ITI-214, its novel selective phosphodiesterase 1 inhibitor for the treatment of motor and non-motor symptoms of Parkinson's Disease, at the American Academy of Neurology Annual Meeting.
The presentation highlighted pre-clinical findings and provided update on the ongoing Phase1/2 trials.
The stock rallied 3.92 percent to $18.54 after hours.
EXACT Sciences Gets Protection From Strong Cologuard Volumes
EXACT Sciences Corporation (NASDAQ:EXAS) reported an 87 percent surge in Q1 revenues to $90.3 million, thanks to a similar percentage increase in Cologuard test volume. The result exceeded the consensus estimate of $86.93 million.
Cologuard is Exact Sciences' FDA-approved and Medicare-covered non-invasive screening test for colon cancer.
The loss per share at 33 cents was narrower than the 37 cents loss estimated by analysts.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
The company forecasts 900,00-920,000 Cologuard tests for the full year 2018.
The stock climbed 5.15 percent to $49.
Vertex' Q1 Beats On Strong CF Revenues
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported non-GAAP EPS of 76 cents on non-GAAP revenues of $638.90 million in Q1. The consensus estimates called for bottom-line results of 62 cents per share on revenues of $617.59 million.
The company reiterated its 2018 total cystic fibrosis product revenue guidance of $2.65 billion to $2.80 billion.
Cytokinetics' Sub-Par Results
Cytokinetics, Inc. (NASDAQ:CYTK) reported below-consensus results for its FQ1.
BioPharmx Gets Facelift From Earnings
Biopharmx Corp (NYSE:BPMX), which develops OTC health and wellness products, reported a narrower-than-expected loss and higher revenues for its Q4 ended Jan. 31.
The penny stock jumped 11.85 percent to $0.235 in after hours.
Sanofi's (NYSE:SNY) Q1 sales down 8.7 percent year-over-year. The company affirmed its full-year growth guidance and announced a buyback program.
Other Events
MediciNova, Inc. (NASDAQ:MNOV) is scheduled to release Phase 1b/2a abstract for its amyotrophic lateral sclerosis candidate MN-166 at the AAN 2018 Annual Meeting
FDA Tidbits
Two FDA directors, namely Dr. Curtis Rosebraugh, who oversees three drug review divisions, and Dr. Donna Gabriel, who is in the charge of gastrointestinal disease drug review committee, are set to retire this week, according to STAT News. These departures will leave three of FDA's 19 drug review divisions without permanent leaders.
Related Links:
Syros Takes The Road Less Traveled In Gene Control, Awaits Windfall From Diverse Indications
LeMaitre Vascular's Lack Of Near-Term Catalysts Pushes Stifel To The Sidelines
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.